Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Bristol-Myers Squibb execs and Starboard Value are back at it today, exchanging broadsides for and against the $74 billion buyout.
There’s not much fresh material …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
